
    
      The primary objective is to compare change from baseline in weekly Average Daily Pain Score
      (ADPS) at Week 14 in Chinese patients with Diabetic Peripheral Neuropathic Pain (DPNP)
      receiving mirogabalin versus placebo.
    
  